PATINA trial demonstrates benefit of palbociclib in HR+ HER2+ metastatic breast cancer
Alliance Foundation Trials, LLC (AFT) and Pfizer Inc. today announced results from the phase III PATINA trial demonstrating that the addition of palbociclib (IBRANCE) to current standard-of-care first-line maintenance therapy…